Suppr超能文献

加拿大艾伯塔省系统性红斑狼疮患者的直接医疗系统成本。

Direct health system costs for systemic lupus erythematosus patients in Alberta, Canada.

机构信息

Department of Health Professions, Manchester Metropolitan University, Manchester, United Kingdom.

Analytics and Performance Reporting Branch, Alberta Health, Edmonton, Canada.

出版信息

PLoS One. 2021 May 7;16(5):e0251409. doi: 10.1371/journal.pone.0251409. eCollection 2021.

Abstract

Systemic lupus Erythematosus (SLE) is a chronic multi-system autoimmune disease that can affect a person's physical, mental, and social life. It imposes a substantial economic burden up on patients, carers, healthcare systems, and wider society. This is the first study to examine the direct health care costs of SLE in Alberta using real-world data. Alberta maintains a publicly funded, universally available health care system. Health service use and direct healthcare costs of SLE and non-SLE cases were determined from inpatient hospital services, fee-for-physician services, emergency services, and ambulatory care services. All costs were estimated for calendar year 2016. Data were analysed using central measures specifically the mean to determine the annual costs of SLE and non-SLE. A total number of 10,932 (Male = 2,546; Female = 8,386), and 41,851,36 (Male = 21,157,76; Female = 20,693,60) of SLE and non-SLE cases, respectively were included in this study. The mean annual costs of SLE, and non-SLE per case were $7,740.19 (Male = $7,986.59; Female = $7,665.38), and $2,479.53 (Male = $2,265.57; Female = $2,698.30), (p < 0.001) respectively. The mean annual costs of fee-for-physician services (SLE = $2,160.03; non-SLE = $840.00) (p < 0.001), inpatient hospital services (SLE = $3,462.86; non-SLE = $1,007.29), (p < 0.001) emergency services (SLE = $440.28; non-SLE = $176.65), (p < 0.001) and ambulatory care services (SLE = $1,677.03; non-SLE = $455.05) (p < 0.001) per case were estimated. The findings showed that the costs of SLE were considerably high for patients and healthcare system. This highlights the importance of appropriate treatment and management of SLE. Further studies are required to fully investigate both the direct and indirect economic burden of SLE including out-of-pocket expenses, costs to patients and caregivers and productivity loss.

摘要

系统性红斑狼疮 (SLE) 是一种慢性多系统自身免疫性疾病,可影响患者的身体、心理和社会生活。它给患者、护理人员、医疗保健系统和更广泛的社会带来了巨大的经济负担。这是第一项使用真实世界数据研究艾伯塔省 SLE 直接医疗保健成本的研究。艾伯塔省维持着一个公共资助的、普遍可用的医疗保健系统。使用住院服务、按服务收费的医生服务、急诊服务和门诊护理服务来确定 SLE 和非 SLE 病例的卫生服务使用情况和直接医疗保健成本。所有成本均按日历年 2016 年进行估算。使用中央措施(特别是平均值)分析数据,以确定 SLE 和非 SLE 的年度成本。本研究共纳入 10932 名(男性=2546 名;女性=8386 名)和 4185136 名(男性=2115776 名;女性=2069360 名)SLE 和非 SLE 病例。SLE 和非 SLE 每例的平均年度成本分别为 7740.19 加元(男性=7986.59 加元;女性=7665.38 加元)和 2479.53 加元(男性=2265.57 加元;女性=2698.30 加元)(p < 0.001)。按服务收费的医生服务(SLE=2160.03 加元;非 SLE=840.00 加元)(p < 0.001)、住院医院服务(SLE=3462.86 加元;非 SLE=1007.29 加元)(p < 0.001)、急诊服务(SLE=440.28 加元;非 SLE=176.65 加元)(p < 0.001)和门诊护理服务(SLE=1677.03 加元;非 SLE=455.05 加元)(p < 0.001)的平均值。研究结果表明,SLE 给患者和医疗保健系统带来的成本相当高。这突出表明 SLE 的适当治疗和管理的重要性。需要进一步研究以充分调查 SLE 的直接和间接经济负担,包括自付费用、患者和护理人员的成本以及生产力损失。

相似文献

1
Direct health system costs for systemic lupus erythematosus patients in Alberta, Canada.
PLoS One. 2021 May 7;16(5):e0251409. doi: 10.1371/journal.pone.0251409. eCollection 2021.
2
Direct and indirect costs for systemic lupus erythematosus in Sweden. A nationwide health economic study based on five defined cohorts.
Semin Arthritis Rheum. 2016 Jun;45(6):684-90. doi: 10.1016/j.semarthrit.2015.11.013. Epub 2015 Dec 2.
5
The humanistic and economic burden of systemic lupus erythematosus : a systematic review.
Pharmacoeconomics. 2013 Jan;31(1):49-61. doi: 10.1007/s40273-012-0007-4.
7
A structured literature review of the direct costs of adult systemic lupus erythematosus in the US.
Arthritis Care Res (Hoboken). 2011 Sep;63(9):1224-32. doi: 10.1002/acr.20502.
10
Real-world medication use and economic outcomes in incident systemic lupus erythematosus patients in the United States.
J Med Econ. 2020 Jan;23(1):1-9. doi: 10.1080/13696998.2019.1678170. Epub 2019 Oct 21.

引用本文的文献

1
Scoping Review of Economic Analyses of Rare Kidney Diseases.
Kidney Int Rep. 2024 Sep 12;9(12):3553-3569. doi: 10.1016/j.ekir.2024.09.004. eCollection 2024 Dec.
4
Exosomes/Extracellular Vesicles and Targeted Tumor Immunotherapy.
Int J Mol Sci. 2024 May 17;25(10):5458. doi: 10.3390/ijms25105458.
5
Incidence and medical costs of lupus in Spanish hospitals: a retrospective database analysis.
Orphanet J Rare Dis. 2024 Feb 16;19(1):74. doi: 10.1186/s13023-024-03077-1.
7
Annual Direct Cost and Cost-Drivers of Systemic Lupus Erythematosus: A Multi-Center Cross-Sectional Study from CSTAR Registry.
Int J Environ Res Public Health. 2023 Feb 16;20(4):3522. doi: 10.3390/ijerph20043522.

本文引用的文献

1
Real-world incidence and prevalence of systemic lupus erythematosus in Alberta, Canada.
Rheumatol Int. 2018 Sep;38(9):1721-1726. doi: 10.1007/s00296-018-4091-4. Epub 2018 Jul 9.
2
Direct and indirect healthcare costs of rheumatoid arthritis patients in Turkey.
Clin Exp Rheumatol. 2016 Nov-Dec;34(6):1033-1037. Epub 2016 Sep 18.
3
The global burden of SLE: prevalence, health disparities and socioeconomic impact.
Nat Rev Rheumatol. 2016 Oct;12(10):605-20. doi: 10.1038/nrrheum.2016.137. Epub 2016 Aug 25.
4
Costs of illness and quality of life in patients with systemic lupus erythematosus in South Korea.
Lupus. 2014 Aug;23(9):949-57. doi: 10.1177/0961203314524849. Epub 2014 Feb 21.
7
The economic burden of systemic lupus erythematosus.
Best Pract Res Clin Rheumatol. 2012 Oct;26(5):695-704. doi: 10.1016/j.berh.2012.08.006.
9
The accuracy of administrative data diagnoses of systemic autoimmune rheumatic diseases.
J Rheumatol. 2011 Aug;38(8):1612-6. doi: 10.3899/jrheum.101149. Epub 2011 May 1.
10
Clinical presentations and outcomes of Filipino juvenile systemic lupus erythematosus.
Pediatr Rheumatol Online J. 2011 Feb 9;9:7. doi: 10.1186/1546-0096-9-7.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验